Notably, soluble recombinant TRAIL demonstrated significant tumor regression without systemic toxicity in animal models [61,62], and this led to clinical development of DR-targeted biologics, such as DR4/5 specific targeted therapy (Table 1, Supplementary Table S1). This evidence concerns the gene TNFSF10 and neoplasm.